Cytokinetics Inc (NASDAQ:CYTK)

6.95
Delayed Data
As of Apr 17
 -0.18 / -2.52%
Today’s Change
3.05
Today|||52-Week Range
13.26
-13.23%
Year-to-Date
Targacept's Diabetic Gastroparesis Drug Fails to Impress - Analyst Blog
Apr 17 / Zacks.com
Oncolytics' Reolysin Filed for Gastric Cancer Orphan Status - Analyst Blog
Apr 09 / Zacks.com
Targacept's Diabetic Gastroparesis Drug Fails to Impress - Analyst Blog
Apr 17 / Zacks.com
Halozyme to Advance PEGPH20 Following FDA Meet - Analyst Blog
Apr 09 / Zacks.com
Celsion Gains on Impressive Breast Cancer Study Data - Analyst Blog
Apr 16 / Zacks.com
Novo Nordisk's Tresiba & Ryzodeg NDAs under FDA Review - Analyst Blog
Apr 09 / Zacks.com
Omeros' OMS721 Available in Europe for Compassionate Use - Analyst Blog
Apr 15 / Zacks.com
Ocular Therapeutix Slumps 19% after Negative Study Data - Analyst Blog
Apr 08 / Zacks.com
Puma Biotechnology Expands Study Cohort for Cancer Drug - Analyst Blog
Apr 15 / Zacks.com
Arena Pharmaceuticals Up on Belviq's New Patent Approval - Analyst Blog
Apr 08 / Zacks.com
Alexion Up as Soliris Gains EU Nod for Label Updates - Analyst Blog
Apr 13 / Zacks.com
Merck KGaA-Pfizer to Co-promote Xalkori for Lung Cancer - Analyst Blog
Apr 08 / Zacks.com
Arena, Eisai Finish Phase I Studies on Obesity Drug Belviq - Analyst Blog
Apr 13 / Zacks.com
Gilead Submits Regulatory Application for HIV Drug in U.S. - Analyst Blog
Apr 08 / Zacks.com
AstraZeneca's Onglyza Briefing Documents Raise Concern - Analyst Blog
Apr 13 / Zacks.com
Alkermes Reports Encouraging Data on Schizophrenia Drug - Analyst Blog
Apr 07 / Zacks.com
Amgen Upgraded to Strong Buy, Perfect for Your Portfolio - Analyst Blog
Apr 13 / Zacks.com
Clovis Oncology's Rucaparib Gets Breakthrough Status - Analyst Blog
Apr 07 / Zacks.com
Adamas Pharma's Lead Candidate Gets Orphan Status in U.S. - Analyst Blog
Apr 13 / Zacks.com
Astellas-Medivation's Xtandi Meets Primary Endpoint - Analyst Blog
Apr 06 / Zacks.com
Horizon Pharma's Actimmune Gets Fast Track Status - Analyst Blog
Apr 13 / Zacks.com
SAGE Therapeutics' Lead Candidate to Enter Phase III Study - Analyst Blog
Apr 06 / Zacks.com
The Medicines Co. Posts Disappointing Preliminary Results - Analyst Blog
Apr 10 / Zacks.com
Nektar Gets Movantik Milestone Payment from AstraZeneca - Analyst Blog
Apr 06 / Zacks.com

To view my watchlist

Not a member yet?

Sign up now for a free account